Mass Spectrometry Imaging of atherosclerosis-affine Gadofluorine following Magnetic Resonance Imaging

Fabian Lohöfer, Rebecca Buchholz, Almut Glinzer, Katharina J. Huber, Helena Haas, Georgios Kaissis, Annette Feuchtinger, Michaela Aichler, Peter B. Sporns, Carsten Höltke, Miriam Stölting, Franz Schilling, René M. Botnar, Melanie A. Kimm, Cornelius Faber, Axel Walch, Alma Zernecke, Uwe Kärst, Moritz WildgruberScientific 2020 · DOI

Abstract

Molecular imaging of atherosclerosis by Magnetic Resonance Imaging (MRI) has been impaired by a lack of validation of the specific substrate responsible for the molecular imaging signal. We therefore aimed to investigate the additive value of mass spectrometry imaging (MSI) of atherosclerosis-affine Gadofluorine P for molecular MRI of atherosclerotic plaques. Atherosclerotic $Ldlr^{-/-}$ mice were investigated by high-field MRI (7 T) at different time points following injection of atherosclerosis-affine Gadofluorine P as well as at different stages of atherosclerosis formation (4, 8, 16 and 20 weeks of HFD). Mass spectrometry imaging allowed for the visualization of the localization and measurement of the concentration of the MR imaging probe Gadofluorine P in plaque tissue ex vivo with high spatial resolution, adding novel and more target-specific information to molecular MR imaging of atherosclerosis.

Introduction

Molecular Magnetic Resonance Imaging (MRI) is a powerful tool for non-invasively assessing atherosclerosis, but it suffers from a "specificity gap." When a clinician observes a signal change, such as T1 shortening in a plaque, it is often difficult to distinguish whether that signal originates from the injected contrast agent or endogenous factors like intraplaque hemorrhage. Traditional validation methods like histology or bulk mass spectrometry (ICP-MS) either fail to visualize the contrast agent directly or lose anatomical context by homogenizing the tissue. This study bridges the gap between macro-scale clinical imaging and micro-scale molecular validation by combining high-field MRI with two types of Mass Spectrometry Imaging (MSI).

Methods

The researchers employed a multi-modal imaging pipeline using an $Ldlr^{-/-}$ mouse model of atherosclerosis (n=48). Mice were divided into groups based on the duration of a high-fat diet (4, 8, 16, and 20 weeks) to represent different stages of disease progression.

  1. In Vivo MRI: Scans were performed at 7 Tesla (7T) to track the kinetics of Gadofluorine P (GfP), an amphiphilic gadolinium-based contrast agent with high affinity for the extracellular matrix (ECM).
  2. MALDI-MSI (Matrix-Assisted Laser Desorption Ionization): This technique detected the intact GfP molecule (m/z 1323), proving the agent remains stable in tissue.
  3. LA-ICP-MS (Laser Ablation Inductively Coupled Plasma MS): Elemental imaging mapped Gadolinium (Gd) at 15 $\mu$m resolution, allowing for precise quantification ($\mu$g of Gd per gram of tissue).
  4. Histology: Sections were stained with Elastica van Gieson to correlate probe accumulation with specific plaque features like the ECM.
Figure 1: Multi-modal imaging approach showing (A) T1 maps, (B) Elastica van Gieson histology, and (C) Gadolinium kinetics in plaque, blood, and muscle.

Results and Key Insights

The study confirmed that Gadofluorine P specifically accumulates in regions rich in extracellular matrix (ECM), such as collagen and tenascin. This explains the increased MRI signal observed as plaques become more advanced and fibrotic.

Quantitative Validation and Kinetics

A significant contribution of this work is the creation of a linear regression model ($Y = 0.00679 \cdot X + 1.54$) relating the MRI relaxation rate (R1) to the actual Gd concentration. This provides a mathematical bridge to estimate probe concentration in vivo based on MRI scans.

  • Peak Accumulation: GfP concentration in plaques peaked at 30 minutes post-injection ($102.4 \pm 22.9 \mu g/g$), while adjacent muscle showed minimal accumulation ($<10 \mu g/g$).
  • Sensitivity: LA-ICP-MS demonstrated a limit of quantification (LOQ) of 197 ng/g, showing extreme sensitivity for detecting trace amounts of the contrast agent.
  • Disease Progression: Both MRI R1 values and MSI-detected Gd concentrations increased significantly from 4 to 20 weeks of a high-fat diet, correlating perfectly with histological evidence of plaque growth.

Discussion and Future Directions

While the study provides a robust validation framework, challenges remain in co-registering 1 mm thick MRI slices with 10 $\mu$m MSI sections due to tissue deformation during excision. Future work should focus on developing deformable image registration software to better align in vivo and ex vivo datasets. Additionally, the authors suggest applying this validation framework to other emerging molecular probes, such as elastin- or collagen-specific agents. By establishing a "ground truth" for non-invasive imaging, this multi-modal approach facilitates the translation of semi-quantitative MRI signals into absolute tissue concentrations.

Summary updated

Abstract

Molecular imaging of atherosclerosis by Magnetic Resonance Imaging (MRI) has been impaired by a lack of validation of the specific substrate responsible for the molecular imaging signal. We therefore aimed to investigate the additive value of mass spectrometry imaging (MSI) of atherosclerosis-affine Gadofluorine P for molecular MRI of atherosclerotic plaques. Atherosclerotic Ldlr<sup>-/-</sup> mice were investigated by high-field MRI (7 T) at different time points following injection of atherosclerosis-affine Gadofluorine P as well as at different stages of atherosclerosis formation (4, 8, 16 and 20 weeks of HFD). At each imaging time point mice were immediately sacrificed after imaging and aortas were excised for mass spectrometry imaging: Matrix Assisted Laser Desorption Ionization (MALDI) Imaging and Laser Ablation - Inductively Coupled Plasma - Mass Spectrometry (LA-ICP-MS) imaging. Mass spectrometry imaging allowed to visualize the localization and measure the concentration of the MR imaging probe Gadofluorine P in plaque tissue ex vivo with high spatial resolution and thus adds novel and more target specific information to molecular MR imaging of atherosclerosis.
BibTeX
@inproceedings{lohofer2020mass,
  author = {Fabian Lohöfer and Rebecca Buchholz and Almut Glinzer and Katharina J. Huber and Helena Haas and Georgios Kaissis and Annette Feuchtinger and Michaela Aichler and Peter B. Sporns and Carsten Höltke and Miriam Stölting and Franz Schilling and René M. Botnar and Melanie A. Kimm and Cornelius Faber and Axel Walch and Alma Zernecke and Uwe Kärst and Moritz Wildgruber},
  title = {{Mass Spectrometry Imaging of atherosclerosis-affine Gadofluorine following Magnetic Resonance Imaging}},
  booktitle = {Scientific},
  year = {2020},
  doi = {10.1038/s41598-019-57075-6},
}
Figure